Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAM-01
- Development stage
- Preclinical
- Lead developer
- CNcure
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SAM-01 is an engineered bacterial therapeutic candidate developed by CNcure, utilizing the company's Salmonella-based Armed Microbe (SAM) platform. The therapy is based on an attenuated strain of *Salmonella typhimurium* that has been genetically modified to selectively target and colonize the hypoxic and necrotic regions of solid tumors. By leveraging the natural tumor-homing properties of Salmonella, SAM-01 acts as a localized delivery vehicle for therapeutic payloads designed to modulate the tumor microenvironment and stimulate a robust anti-tumor immune response. The program is currently in the lead optimization stage for the treatment of various solid cancers.
- Other names
- SAM-01SAM01SAM 01
02
Targets
TLR5 (Toll-like receptor 5)HA (Hyaluronic acid)
Beyond the preview
Go deeper on SAM-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAM-01.